Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics

Trial Identifier: D3250C00040
Sponsor: AstraZeneca
NCTID:: NCT02821416
Start Date: October 2016
Primary Completion Date: October 2019
Study Completion Date: October 2019
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
French Translation

Trial Locations

Country Location
Canada, AB Calgary, AB, Canada, T2N 4Z6
Canada, AB Edmonton, AB, Canada, T6G 2B7
Canada, BC Vancouver, BC, Canada, V5Z 1M9
Canada, ON Hamilton, ON, Canada, L8N 3Z5
Canada, QC Quebec, QC, Canada, G1V 4G5
Canada, SK Saskatoon, SK, Canada, S7N 0W8